T

he $500,000 Lemelson-MIT Prize is being awarded this year to bioengineer Feng Zhang, a key developer of CRISPR genome-editing technology, the prize jury announced on Tuesday.

Although Zhang, whose lab is at the Broad Institute of MIT and Harvard, is best known for CRISPR advances such as editing genes in human and mouse cells, he wasn’t honored only for that, said bioengineer Michael Cima of MIT’s Koch Institute, the faculty director of the award.

Unlock this article by subscribing to STAT Plus. Try it FREE for 30 days!

SUBSCRIBE TODAY

What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Morning Rounds newsletter

Your daily dose of what’s new in health and medicine.

Privacy Policy